JP2009542820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542820A5 JP2009542820A5 JP2009530701A JP2009530701A JP2009542820A5 JP 2009542820 A5 JP2009542820 A5 JP 2009542820A5 JP 2009530701 A JP2009530701 A JP 2009530701A JP 2009530701 A JP2009530701 A JP 2009530701A JP 2009542820 A5 JP2009542820 A5 JP 2009542820A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- selective antagonist
- antidepressant
- selective
- telenzepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims description 41
- 239000000935 antidepressant agent Substances 0.000 claims description 27
- 229940005513 antidepressants Drugs 0.000 claims description 27
- 230000001430 anti-depressive effect Effects 0.000 claims description 24
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 229950004351 telenzepine Drugs 0.000 claims description 15
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 14
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 14
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000004580 weight loss Effects 0.000 claims description 10
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 8
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 8
- 229960001653 citalopram Drugs 0.000 claims description 8
- 229960002073 sertraline Drugs 0.000 claims description 8
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 8
- 229960004688 venlafaxine Drugs 0.000 claims description 8
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000000883 anti-obesity agent Substances 0.000 claims description 4
- 229940125710 antiobesity agent Drugs 0.000 claims description 4
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 3
- 235000019789 appetite Nutrition 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 2
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 2
- 229960001623 desvenlafaxine Drugs 0.000 claims description 2
- 229960002866 duloxetine Drugs 0.000 claims description 2
- -1 ecitalopram Chemical compound 0.000 claims description 2
- 229960002464 fluoxetine Drugs 0.000 claims description 2
- 229960004038 fluvoxamine Drugs 0.000 claims description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 2
- 229960000600 milnacipran Drugs 0.000 claims description 2
- 229960001785 mirtazapine Drugs 0.000 claims description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 229960002296 paroxetine Drugs 0.000 claims description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004633 pirenzepine Drugs 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 2
- 230000000697 serotonin reuptake Effects 0.000 claims description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
- 229960004425 sibutramine Drugs 0.000 claims description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 2
- 239000003174 triple reuptake inhibitor Substances 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
- 229940111055 Serotonin-norepinephrine-dopamine reuptake inhibitor Drugs 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940053544 other antidepressants in atc Drugs 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80506606P | 2006-06-16 | 2006-06-16 | |
| US60/805,066 | 2006-06-16 | ||
| US82922506P | 2006-10-12 | 2006-10-12 | |
| US60/829,225 | 2006-10-12 | ||
| US11/763,313 US8748419B2 (en) | 2006-06-16 | 2007-06-14 | Treating obesity with muscarinic receptor M1 antagonists |
| US11/763,313 | 2007-06-14 | ||
| PCT/US2007/071374 WO2007147134A2 (en) | 2006-06-16 | 2007-06-15 | Treating obesity with muscarinic receptor m1 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013001003A Division JP2013079277A (ja) | 2006-06-16 | 2013-01-08 | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009542820A JP2009542820A (ja) | 2009-12-03 |
| JP2009542820A5 true JP2009542820A5 (cg-RX-API-DMAC7.html) | 2011-07-14 |
| JP5371762B2 JP5371762B2 (ja) | 2013-12-18 |
Family
ID=38832915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530701A Expired - Fee Related JP5371762B2 (ja) | 2006-06-16 | 2007-06-15 | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 |
| JP2013001003A Withdrawn JP2013079277A (ja) | 2006-06-16 | 2013-01-08 | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013001003A Withdrawn JP2013079277A (ja) | 2006-06-16 | 2013-01-08 | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8748419B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2031964B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5371762B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101442525B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007260642B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0713728A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2655323C (cg-RX-API-DMAC7.html) |
| IL (1) | IL195858A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008015886A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ573571A (cg-RX-API-DMAC7.html) |
| SG (1) | SG172711A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007147134A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200810681B (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110021507A1 (en) * | 2009-07-22 | 2011-01-27 | Theracos, Inc. | Inhibiting antipsychotic-induced weight gain |
| US8440655B2 (en) | 2010-06-21 | 2013-05-14 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
| PT2632468T (pt) * | 2010-10-25 | 2018-03-02 | Univ Manitoba | Composições terapêuticas para polineuropatia diabética simétrica |
| WO2013151596A2 (en) * | 2012-04-05 | 2013-10-10 | Finch Linda Duerler | System and method of losing weight |
| DK3429625T3 (da) | 2016-03-15 | 2023-07-03 | Univ London Queen Mary | Fremgangsmåde til behandling af fedme |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1795183B1 (de) | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
| US4172831A (en) | 1974-11-26 | 1979-10-30 | Lilly Industries Limited | Thieno-benzodiazepines |
| US3953430A (en) | 1975-02-24 | 1976-04-27 | American Cyanamid Company | Substituted benzodiazepin-10-ones and method of use |
| US4168269A (en) | 1978-04-12 | 1979-09-18 | American Cyanamid Company | Substituted thieno-benzodiazepines |
| US4381301A (en) | 1980-05-07 | 1983-04-26 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments |
| US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| EP0386145A1 (de) | 1987-12-22 | 1990-09-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thienotricyclen zur behandlung von erkrankungen der bronchien |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5668155A (en) | 1988-05-10 | 1997-09-16 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| US5585347A (en) * | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
| IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5312817A (en) | 1991-05-14 | 1994-05-17 | Ernir Snorrason | Treatment of fatigue syndrome |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5324832A (en) | 1991-07-03 | 1994-06-28 | The United States Of America As Represented By The Department Of Health And Human Services | Muscarinic antagonists |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| FR2710265B1 (fr) | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| DE19541260A1 (de) | 1995-11-06 | 1997-05-07 | Lohmann Therapie Syst Lts | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| PT863136E (pt) | 1997-02-25 | 2004-01-30 | Akzo Nobel Nv | Derivados de azetidina e de pirrolidina |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| US6599529B1 (en) | 1997-09-11 | 2003-07-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs) |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6248864B1 (en) | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| WO1999038501A2 (en) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6312717B1 (en) | 1998-07-07 | 2001-11-06 | Bristol-Myers Squibb Company | Method for treatment of anxiety and depression |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| CN1406126A (zh) | 1998-10-01 | 2003-03-26 | 诺瓦提斯公司 | 新型缓释口服制剂 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2792527B1 (fr) | 1999-04-22 | 2004-08-13 | Ethypharm Lab Prod Ethiques | Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques |
| US6541020B1 (en) | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
| US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| ATE376414T1 (de) | 1999-09-02 | 2007-11-15 | Nostrum Pharmaceuticals Inc | Pellet formulierung mit gesteuerter freisetzung |
| US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| US6080736A (en) | 1999-10-27 | 2000-06-27 | Janus Pharmaceuticals, Inc. | Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| AU2463701A (en) | 1999-12-29 | 2001-07-09 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
| WO2002022579A2 (en) * | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| US6482440B2 (en) | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| KR20110043664A (ko) * | 2002-05-17 | 2011-04-27 | 듀크 유니버시티 | 비만치료방법 |
| WO2004078113A2 (en) * | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US20050226920A1 (en) * | 2004-04-13 | 2005-10-13 | Kirk Voelker | Method of decreasing nicotine withdrawal symptoms during smoking cessation. |
| CA2553309A1 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| JP2008509147A (ja) | 2004-08-05 | 2008-03-27 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
| EP1874356A2 (en) * | 2005-04-15 | 2008-01-09 | Board of Trustees of Michigan State University | Aminergic pharmaceutical compositions and methods |
| US8859585B2 (en) | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| JP2009530697A (ja) | 2006-03-14 | 2009-08-27 | エヌエックスピー ビー ヴィ | 自動設定可能なスマートカードおよびスマートカードの自動設定方法 |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| CN101472476B (zh) | 2006-06-16 | 2013-10-30 | 泰拉科斯有限公司 | 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用 |
-
2007
- 2007-06-14 US US11/763,313 patent/US8748419B2/en not_active Expired - Fee Related
- 2007-06-15 NZ NZ573571A patent/NZ573571A/en not_active IP Right Cessation
- 2007-06-15 AU AU2007260642A patent/AU2007260642B2/en not_active Ceased
- 2007-06-15 BR BRPI0713728-1A patent/BRPI0713728A2/pt not_active IP Right Cessation
- 2007-06-15 JP JP2009530701A patent/JP5371762B2/ja not_active Expired - Fee Related
- 2007-06-15 WO PCT/US2007/071374 patent/WO2007147134A2/en not_active Ceased
- 2007-06-15 MX MX2008015886A patent/MX2008015886A/es active IP Right Grant
- 2007-06-15 KR KR1020097000755A patent/KR101442525B1/ko not_active Expired - Fee Related
- 2007-06-15 CA CA2655323A patent/CA2655323C/en not_active Expired - Fee Related
- 2007-06-15 EP EP07812168.8A patent/EP2031964B1/en not_active Not-in-force
- 2007-06-15 SG SG2011043874A patent/SG172711A1/en unknown
-
2008
- 2008-12-11 IL IL195858A patent/IL195858A/en active IP Right Grant
- 2008-12-18 ZA ZA2008/10681A patent/ZA200810681B/en unknown
-
2013
- 2013-01-08 JP JP2013001003A patent/JP2013079277A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542819A5 (cg-RX-API-DMAC7.html) | ||
| JP2012036212A5 (cg-RX-API-DMAC7.html) | ||
| JP2013544850A5 (cg-RX-API-DMAC7.html) | ||
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| JP2008528510A5 (cg-RX-API-DMAC7.html) | ||
| JP2023100904A5 (cg-RX-API-DMAC7.html) | ||
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| JP2005523334A5 (cg-RX-API-DMAC7.html) | ||
| JP2009542820A5 (cg-RX-API-DMAC7.html) | ||
| RU2007103313A (ru) | Комбинация бупропина и другого состава для эффективной потери веса | |
| JP2016506933A5 (cg-RX-API-DMAC7.html) | ||
| JP2010534676A5 (cg-RX-API-DMAC7.html) | ||
| JP2009538331A5 (cg-RX-API-DMAC7.html) | ||
| JP2015535290A5 (cg-RX-API-DMAC7.html) | ||
| JP2013543482A5 (cg-RX-API-DMAC7.html) | ||
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| Rogóz et al. | Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats | |
| JP2020533415A5 (cg-RX-API-DMAC7.html) | ||
| JP2015534563A5 (cg-RX-API-DMAC7.html) | ||
| Reeves et al. | ICase Report | |
| KR20060032598A (ko) | 세로토닌 재흡수 억제제 및 아고멜라틴의 조합 | |
| JP2007513052A5 (cg-RX-API-DMAC7.html) | ||
| CO6260011A2 (es) | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico | |
| JP2007505156A5 (cg-RX-API-DMAC7.html) | ||
| RU2009101146A (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 |